Abstract
Agilent Technologies, Inc. will report quarterly results on November 23, 2026 Post-Mkt; this preview consolidates the latest actuals and forecasts on revenue, margins, net income, and EPS, and frames what to watch in services, diagnostics, and digital pathology initiatives.Market Forecast
Based on the latest forecasts, Agilent Technologies, Inc. is projected to deliver revenue of 1.99 billion US dollars this quarter, up 8.46% year over year, with estimated EPS of 1.73 (up 8.95% year over year) and estimated EBIT of 565.12 million US dollars (up 14.63% year over year). Forecasts provided do not specify a gross margin or net margin for the quarter; the prior-quarter gross margin baseline was 55.54%, which will be a key reference point for evaluating mix and pricing dynamics. The company’s main revenue engines remain services and consumables alongside instruments: last quarter Agilent CrossLab Services contributed 786.00 million US dollars, the Life Sciences and Diagnostics portfolio contributed 746.00 million US dollars, and Applied Markets contributed 346.00 million US dollars; the balance of services and instruments continues to shape overall profitability and earnings quality. We view the most promising segment to be the expanding diagnostics and digital pathology stack—reinforced by the announced acquisition of Proscia and the US launch of the S540md slide scanning system—where Proscia’s past 12-month revenue exceeded 18.00 million US dollars and adds a recurring software component that can compound over time.Last Quarter Review
Agilent Technologies, Inc. reported revenue of 1.88 billion US dollars last quarter (up 8.06% year over year), a gross profit margin of 55.54%, GAAP net profit attributable to the parent company of 362.00 million US dollars, a net profit margin of 19.28%, and adjusted EPS of 1.62 (up 18.25% year over year). A notable highlight was operating leverage: EBIT reached 532.00 million US dollars, up 25.47% year over year, while net profit increased sequentially by 6.78% as cost discipline and mix efficiency flowed through to the bottom line. By business line, Agilent CrossLab Services generated 786.00 million US dollars, Life Sciences and Diagnostics delivered 746.00 million US dollars, and Applied Markets contributed 346.00 million US dollars; this spread underscored a balanced mix of recurring services and product shipments that supported margin resilience.Current Quarter Outlook
Core Operations and Recurring Services
The prior quarter’s profile shows a company leaning into recurring revenue and lifetime support, with Agilent CrossLab Services accounting for 786.00 million US dollars. The upcoming quarter’s earnings calculus leans heavily on similar themes. Consumables and services reorder cadence tends to stabilize revenue, and the sequential interplay between services and instruments influences gross margin around the mid-50s baseline observed last quarter. With the current-quarter revenue estimate at 1.99 billion US dollars and an EPS estimate of 1.73, the services contribution rate will be essential in bridging any instrument shipment variability, particularly as services often carry structurally higher margins than hardware. A steady services mix also supports cash generation, which in turn provides flexibility for buybacks and integration spending.EBIT is forecast at 565.12 million US dollars, up 14.63% year over year, signaling an expectation of operating leverage despite uneven instrument procurement cycles. If the services mix holds or improves, that leverage is likely anchored in lower-cost absorption on a per-unit basis and disciplined operating expense management. The company’s last quarter margin profile, with gross margin at 55.54% and net margin at 19.28%, provides a strong starting point; the quarter-to-quarter net profit uptick of 6.78% signals that cost structures remain in check. The extent to which services and consumables refill rates keep pace with instrument deliveries will be visible in the gross margin outcome and will likely feed through to EPS performance versus the 1.73 estimate.
A crucial detail for this quarter is price and mix. Pricing actions implemented across service contracts, software entitlements, and consumables typically lag initial instrument sales, meaning the aggregate revenue composition matters as much as volume. Instrument-heavy quarters can depress gross margin if services lag, while a richer services mix usually lifts profitability. The last quarter’s combination delivered robust adjusted EPS growth of 18.25% year over year, aided by EBIT growth of 25.47%; maintaining even a portion of that cadence requires disciplined execution on renewal rates, multi-year service agreements, and timely deliveries that align with customer commissioning schedules. The forecast models imply confidence that this playbook continues into the present quarter.
Digital Pathology and Diagnostics Software
The current quarter includes an elevated focus on digital pathology and associated software, catalyzed by the announced plan to acquire Proscia for up to 270.00 million US dollars and the US introduction of the S540md slide scanning system. Proscia’s past 12-month revenue exceeded 18.00 million US dollars, and while that is modest versus the company total, the software-led, subscription-capable nature of digital pathology can help expand recurring revenue and enhance margins over time. The acquisition structure, which includes contingent consideration tied to milestones, suggests an integration roadmap aligned to commercialization goals. This quarter, investors will look for color on the expected closing timeline, pipeline conversion, and early cross-sell opportunities across the installed base.The significance of the digital pathology stack lies in the ability to integrate scanners, image management, and AI-enabled workflows with broader diagnostics instrumentation and services. Near-term, the revenue step-up from Proscia will be limited until consolidation occurs, but the strategic signal is clear: it broadens the software and data layer that can be sold into existing enterprise accounts. This quarter’s revenue estimate of 1.99 billion US dollars does not explicitly break out digital pathology, but commentary around bookings, backlog, and early demand indicators for the S540md will be especially relevant. A positive inflection in orders or deployments—even if not yet material to totals—can reinforce the trajectory implied by the EBIT growth estimate of 14.63% year over year.
The contribution profile of diagnostics and digital solutions also matters for long-term margin trajectory. Software gross margins typically exceed those of capital equipment, and support agreements can compound over multi-year terms. If management confirms traction in digital pathology adoption, it could provide visibility for sustained EPS growth beyond this quarter’s 1.73 estimate. Conversely, integration timing and regulatory or implementation cycles can elongate revenue recognition. The market will likely parse management’s remarks for clarity on the cadence of revenue conversion, deferred revenue trends, and any incremental operating expenses associated with integration and go-to-market scale-up.
Key Stock Price Drivers This Quarter
Three variables appear most likely to shape the stock reaction around the print: the revenue/EPS spread to estimates, margin signals relative to last quarter’s 55.54% gross margin baseline, and updates on capital deployment and integration items. On revenue, the 1.99 billion US dollars estimate implies healthy year-over-year growth of 8.46%; if the company demonstrates outperformance without sacrificing margins, the leverage implied in the 565.12 million US dollars EBIT estimate could drive a favorable EPS delta versus the 1.73 consensus. Investors will also look for confirmation that last quarter’s net margin of 19.28% remains a reasonable anchor given the expected mix.On margins and mix, commentary around services renewal rates and consumables throughput versus instrument shipments will be a central tell. The last quarter’s adjusted EPS growth of 18.25% year over year benefited from both mix and expense control; sustaining that momentum would likely require continued efficiency in delivery, a disciplined pricing framework for services, and steady instrument order conversion. Any deviation—either a heavier instrument weighting without matching services or a step-up in operating expenses beyond plan—could modulate the EPS outcome.
Capital deployment and corporate actions form the third lens. Recent disclosures highlighted share repurchases and the planned Proscia acquisition. This quarter, investors will expect updates on buyback pacing relative to cash generation, as well as integration milestones for digital pathology. Clarity on the costs to close, expected revenue recognition timing, and early customer adoption patterns could influence how investors capitalize earnings beyond this quarter. Additionally, the launch updates for the S540md slide scanning system—and any initial uptake signals—will feed into near-term valuation frameworks, especially if management indicates a pipeline consistent with the revenue and EBIT growth outlined by forecasts.
Analyst Opinions
The balance of recent analyst commentary is bullish. Among the collected views over the last several months, at least five notable institutions maintained or initiated Buy/Overweight ratings, while one maintained Hold, implying an approximate 83% bullish and 17% neutral split. Bernstein reiterated Buy with a 180.00 US dollars price target on October 16, 2026, citing improving earnings power and supportive mix. Stifel Nicolaus reiterated Buy with a 180.00 US dollars target, emphasizing near-term execution and recurring revenue durability. Goldman Sachs maintained Buy with a 155.00 US dollars price target, indicating confidence in earnings trajectories aligned with service and consumables steadiness. Barclays maintained Buy with a 145.00 US dollars target, suggesting the valuation remains attractive given expected revenue and EPS growth. Evercore ISI kept an Overweight rating while adjusting its target to 172.00 US dollars, a move that still reflects a constructive stance despite recalibrated assumptions. Separately, Deutsche Bank initiated Buy with a 190.00 US dollars target, underscoring expected growth through both core operations and incremental contributions from digital initiatives. Piper Sandler reiterated Hold with a 150.00 US dollars target, representing the minority view within the recent sample.The bullish case coalesces around three factors. First, the forecasted revenue of 1.99 billion US dollars (up 8.46% year over year) and EPS of 1.73 (up 8.95% year over year) signal a return to balanced growth with solid earnings quality, aided by the services mix and disciplined cost control. Second, the prior quarter’s gross margin of 55.54% and net margin of 19.28%, together with EBIT growth of 25.47% year over year, provide an empirical base that supports the 14.63% year-over-year EBIT growth projected for this quarter. Third, the diagnostics and digital pathology expansion—anchored by the Proscia acquisition plan and the S540md scanner—offers an incremental growth vector that strategists expect to enhance recurring software revenue and compound margins over time.
In their majority perspective, analysts frame the setup as one where execution against services renewal and instrument backlog conversion dictates whether EPS clears the 1.73 bar. The constructive stance reflects confidence in the ability to maintain or modestly improve mix while scaling newer software and digital solutions. Any early signals that digital pathology bookings are accelerating, or that services intensity remains high relative to instruments, would reinforce these Buy/Overweight viewpoints. Conversely, the minority Hold view emphasizes the need to validate that the recent step-up in EBIT and EPS can be sustained without incremental operating expense drag as new offerings scale. Overall, the prevailing institutional view is that the present quarter’s growth and profitability profile is favorable, with upside potential if mix and execution stay aligned with the forecast ranges.
Comments